Downloads

  1. Executive Order For Psychedelics 5/8/2026

    We caught up with Joseph Tucker, Ph.D., CEO of Enveric Biosciences, to discuss the executive order for psychedelics.

  2. Precision By Design: Drug Innovation Through Structure-Based Drug Design (SBDD) 5/6/2026

    Leverage structure-based drug design to gain deeper molecular insights, prioritize high-potential candidates, and accelerate your path from discovery to clinic.

  3. Accelerating Small Molecule Protein Degrader Development Using High-Content Imaging 5/6/2026

    High‑content imaging enables rapid discovery and optimization of small‑molecule protein degraders by delivering multiparametric, single‑cell insights that accelerate hit identification, SAR development, and lead advancement.

  4. GLP-1 Receptor Agonists: Metabolism, Reward Biology, And AI-Driven Drug Discovery 5/6/2026

    For drug discovery teams, the central question is whether metabolic signaling pathways can serve as a tractable new entry point into addiction therapeutics.

  5. GLP-1 And Addiction: Mechanism, Missteps, And What Comes Next 5/4/2026

    Evidence suggests GLP-1R agonists may influence reward pathways and craving, raising important questions for addiction research and drug development.

  6. Using Full DEL Data To Improve Early Compound Decisions 4/29/2026

    High-throughput screens hold insights beyond individual hits. Examine a broader view of screening data that reveals structure–function patterns to guide smarter compound prioritization.

  7. GLP-1 Agonists In Addiction: Rationale And Drug Development 4/24/2026

    GLP-1 receptor agonists represent a scientifically credible and potentially consequential avenue in addiction medicine.

  8. Why Rare Cancers Are Often Left Behind In Drug Discovery 4/23/2026

    Combining advances in AI with continued investment in rare cancer research could help bring new treatment options to patients who currently have very few.

  9. Why Cell And Gene Therapies Break After Early Success 4/22/2026

    The field has largely solved how to trigger biology, and yet, many programs still fail because what happens cannot be sustained, controlled, or directed over time.

  10. Unlocking The Next Wave Of Cancer Vaccines 4/21/2026

    Discover how advanced ionizable LNP formulations and scalable manufacturing strategies can accelerate the development and clinical translation of personalized cancer vaccines.